ZhuJMPolskyD. Private equity and physician medical practices—navigating a changing ecosystem. N Engl J Med. 2021;384(11):981-983. doi:10.1056/NEJMP2032115.
2.
TanneJH. US Congress investigates effects of $80bn private equity industry on government healthcare programme. BMJ. 2020;370:m3490. doi:10.1136/BMJ.M3490.
3.
BruchJZeltzerDSongZ. Characteristics of private equity–owned hospitals in 2018. Ann Intern Med. 2021;174(2):277-279. doi:10.7326/M20-1361.
4.
BruchJDGondiSSongZ. Changes in hospital income, use, and quality associated with private equity acquisition. JAMA Intern Med. 2020;180(11):1428-1435. doi:10.1001/JAMAINTERNMED.2020.3552.
5.
ResneckJS. Dermatology practice consolidation fueled by private equity investment: potential consequences for the specialty and patients. JAMA Dermatol. 2018;154(1):13-14. doi:10.1001/JAMADERMATOL.2017.5558.
6.
KondaSFrancisJMotaparthiKGrant-KelsJM, Group for Research of Corporatization and Private Equity in Dermatology. Future considerations for clinical dermatology in the setting of 21st century American policy reform: corporatization and the rise of private equity in dermatology. J Am Acad Dermatol. 2019;81(1):287-296.e8. doi:10.1016/j.jaad.2018.09.052.
7.
KayeDRLuckenbaughANOerlineM, et al. Understanding the costs associated with surgical care delivery in the Medicare population. Ann Surg. 2020;271(1):23-28. doi:10.1097/SLA.0000000000003165.
8.
ZhuJMHuaLMPolskyD. Private equity acquisitions of physician medical groups across specialties 2013-2016. JAMA. 2020;323(7):663-665. doi:10.1001/JAMA.2019.21844.
9.
TanSSeigerKRenehanPMostaghimiA. Trends in private equity acquisition of dermatology practices in the United States. JAMA Dermatol. 2019;155(9):1013-1021. doi:10.1001/JAMADERMATOL.2019.1634.
10.
BraunRTBondAMQianYZhangMCasalinoLP. Private equity in dermatology: effect on price, utilization, and spending. Health Aff. 2021;40(5):727-735. doi:10.1377/HLTHAFF.2020.02062.
11.
NoviceTPortneyDEshaqM. Dermatology resident perspectives on practice ownership structures and private equity-backed group practices. Clin Dermatol. 2020;38(3):296-302. doi:10.1016/j.clindermatol.2020.02.008.
12.
O’DonnellEMLelliGJBhidyaSCasalinoLP. The growth of private equity investment in health care: perspectives from ophthalmology. Health Aff. 2020;39(6):1026-1031. doi:10.1377/HLTHAFF.2019.01419.
13.
KhanMASridharJKuriyanAEHoAC. Private equity transactions: perceptions of U.S. Ophthalmol Retina. 2021;5(8):832-834. doi:10.1016/j.oret.2020.12.014.
14.
KhetpalSLopezJSteinbacherDM. Trends in private equity deals in oral and maxillofacial surgery and dentistry. J Oral Maxillofac Surg. 2021;79(3):513-515. doi:10.1016/j.joms.2020.10.010.
15.
PatelNAAfsharS. Implications of private equity in oral and maxillofacial surgery. J Oral Maxillofac Surg. 2020;78(9):1456-1458. doi:10.1016/j.joms.2020.03.046.
16.
BruchJDBorsaASongZRichardsonSS. Expansion of private equity involvement in women’s health care. JAMA Intern Med. 2020;180(11):1542-1545. doi:10.1001/JAMAINTERNMED.2020.3567.
17.
KhetpalSLopezJSteinbacherDM. Private equity in plastic surgery: a nine-year analysis. Plast Reconstr Surg. 2021;148(6):1088E-1090E. doi:10.1097/PRS.0000000000008536.
